Bladder perfusion pharmaceutical composition, preparation method therefor and application thereof
US-2024398841-A1 · Dec 5, 2024 · US
Use of Danshensu, Notoginsenoside R1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder
US9101640B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9101640-B2 |
| Application number | US-201013505051-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 4, 2010 |
| Priority date | Nov 5, 2009 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a new use of traditional Chinese drug products of Danshensu (DLA), Notoginsenoside R1 (R1) and their combination, in particular to the therapeutic and preventive effects of DLA, R1 and their combination on the diseases caused by microcirculation disorder.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating at least one disease caused by a microcirculation disorder resulting from ischemia-reperfusion in a subject, the method comprising administering an effective amount of a first medicine prepared from a first combination of Danshensu and Notoginsenoside R1 to the subject, the Danshensu having a weight ratio relative to the Notoginsenoside R1 in a range of about 1:4 to about 4:1, wherein the at least one disease caused by the microcirculati…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9101640B2 cover?
- The present invention relates to a new use of traditional Chinese drug products of Danshensu (DLA), Notoginsenoside R1 (R1) and their combination, in particular to the therapeutic and preventive effects of DLA, R1 and their combination on the diseases caused by microcirculation disorder.
- Who is the assignee on this patent?
- Han Jingyan, Guo Jun, Yang Jiying, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/704. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).